Summary by Futu AI
Jike Pharmaceutical-B (02171.HK) announced on March 1, 2024 that its fully human B-cell maturation antigen (BCMA) autologous CAR-T cell product, Saikeze®, has been approved for listing by the National Medical Products Administration (NMPA) for the treatment of relapsed or refractory multiple myeloma (R/R MM) in adult patients. In addition, the company has signed a cooperation agreement with a wholly-owned subsidiary of Huadong Medicine Co., Ltd. to jointly commercialize Saikeze®. As of July 31, 2024, Saikeze® has been included in the insurance coverage of nearly 20 provinces or cities and has received 52 orders from Huadong Medicine. The company expects the sales revenue of Saikeze® to further accelerate with the continued marketing activities and the expansion of insurance coverage. In terms of finance, for the six months ended June 30, 2024, the company's revenue was approximately RMB 6 million, gross profit was approximately RMB 2 million, and net loss was approximately RMB 352 million, a decrease of approximately RMB 52 million from the same period last year. The cash and bank balance is approximately RMB 1,653 million.
